Peplin

Latest Peplin news

news

09-June-09

Peplin Initiates Phase 3 Clinical Trials with PEP005 Gel in AK on Face and Scalp read more

28-May-09

Peplin's Positive Phase II AK Trial Results Published in JAAD read more

17-May-09

Positive Results for Peplin's First Phase III AK Trial read more

15-May-09

Peplin Results for the Quarter Ended 31 March 2009 read more

›› More News

Clinical trials

For information regarding Peplin's PEP005 (ingenol mebutate) Gel clinical trial programme or to find a participating centre. Please refer to: www.clinicaltrials.gov and type "peplin" in the search box. Alternatively, key clinical trials are summarized below.

Current studies

Reference Development Phase Status Indication No. of Patients Additional information
REGION-IIb Phase III Enrolment ongoing AK, Head 250 See press release
REGION-IIa Phase III Enrolment ongoing AK, Head 250 See press release
PEP005-009 Phase IIa Ongoing sBCC 58 (est) See press release

Completed studies

Reference Development Phase Status Indication No. of Patients Additional information
REGION-I Phase III Completed May 2009 AK, Non-Head 250 See press release
PEP005-015 Phase IIb Completed March 2009  AK, Head 240  See press release
PEP005-007 Phase II Completed December 2007 AK, face or face and scalp 88 See press release
PEP005-006 Phase II Completed June 2007 AK, body and scalp 222 See press release
PEP005-022 Phase IIb Completed late 2008 AK extensor forearm 64 Open label safety study
PEP005-008 Phase II Completed March 2007 Cutaneous squamous cell carcinoma 25 See press release
PEP005-002 Phase IIa Completed July 2006 Safety in nodular basal cell carcinoma 58 See press release
PEP005-003 Phase IIa Completed April 2006 Safety in superficial basal cell carcinoma 60 See press release
PEP005-004 Phase IIa Completed February 2006 Safety in AK 22 See press release
PEP005-001 Phase IIa Completed November 2005 Safety in AK 63 See press release
PEP005-005 Phase I Completed October 2006 Safety – Specifically : sensitisating potential of PE0005 in healthy volunteers 238 There were no reactions greater than minimal erythema at any time during induction

For further information please contact us at info@peplin.com